Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2021 16:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference

SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
September 08, 2021 16:05 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
September 01, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Participate In Upcoming Investor Conferences

SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
August 16, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors

SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
August 11, 2021 16:01 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib

SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
August 09, 2021 16:02 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates

Phase 1/2 TRIDENT-1 Enrollment Reaches Approximately 300 Patients, Including More than 50 in the ROS1-Positive TKI-naïve NSCLC Cohort (EXP-1)TPX-0022 Granted Fast Track Designation in MET Amplified...
July 28, 2021 16:15 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Host Second Quarter 2021 Conference Call

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
June 29, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer

SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
June 17, 2021 08:30 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
June 01, 2021 09:00 ET | Source: Turning Point Therapeutics, Inc.

Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference

SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...